Joshua A Mccarroll

List of Publications by Year
in descending order

74 papers	4,498 citations	147726 31 h-index	114418 63 g-index
80 all docs	80 docs citations	80 times ranked	7387 citing authors

#	Article	IF	Citations
1	miR-99b-5p, miR-380-3p, and miR-485-3p are novel chemosensitizing miRNAs in high-risk neuroblastoma. Molecular Therapy, 2022, 30, 1119-1134.	3.7	5
2	Î²III-Tubulin Structural Domains Regulate Mitochondrial Network Architecture in an Isotype-Specific Manner. Cells, 2022, 11, 776.	1.8	2
3	Intranasal Delivery of Recombinant S100A8 Protein Delays Lung Cancer Growth by Remodeling the Lung Immune Microenvironment. Frontiers in Immunology, 2022, 13, .	2.2	6
4	Ex vivo culture of intact human patient derived pancreatic tumour tissue. Scientific Reports, 2021, 11, 1944.	1.6	27
5	Facile synthesis of lactoferrin conjugated ultra small large pore silica nanoparticles for the treatment of glioblastoma. Nanoscale, 2021, 13, 16909-16922.	2.8	28
6	Induction of muscle-regenerative multipotent stem cells from human adipocytes by PDGF-AB and 5-azacytidine. Science Advances, 2021, 7, .	4.7	3
7	The RNAâ€helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma. Molecular Oncology, 2021, 15, 1162-1179.	2.1	12
8	Cancer-Associated Fibroblasts in Pancreatic Ductal Adenocarcinoma Determine Response to SLC7A11 Inhibition. Cancer Research, 2021, 81, 3461-3479.	0.4	62
9	Does the Microenvironment Hold the Hidden Key for Functional Precision Medicine in Pancreatic Cancer?. Cancers, 2021, 13, 2427.	1.7	6
10	Identification of Novel Medulloblastoma Cell-Targeting Peptides for Use in Selective Chemotherapy Drug Delivery. Journal of Medicinal Chemistry, 2020, 63, 2181-2193.	2.9	18
11	Targeting the undruggable in pancreatic cancer using nano-based gene silencing drugs. Biomaterials, 2020, 240, 119742.	5.7	46
12	Phenotypic screen for oxygen consumption rate identifies an anti-cancer naphthoquinone that induces mitochondrial oxidative stress. Redox Biology, 2020, 28, 101374.	3.9	9
13	Modulating the Selectivity and Stealth Properties of Ellipsoidal Polymersomes through a Multivalent Peptide Ligand Display. Advanced Healthcare Materials, 2020, 9, e2000261.	3.9	11
14	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene, 2019, 38, 3824-3842.	2.6	17
15	The Use of Star Polymer Nanoparticles for theÂDelivery of siRNA to Mouse Orthotopic Pancreatic Tumor Models. Methods in Molecular Biology, 2019, 1974, 329-353.	0.4	8
16	Drugging MYCN Oncogenic Signaling through the MYCN-PA2G4 Binding Interface. Cancer Research, 2019, 79, 5652-5667.	0.4	24
17	Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma. Molecular Cancer Therapeutics, 2018, 17, 1012-1023.	1.9	33
18	Nucleic acid hybridization on an electrically reconfigurable network of gold-coated magnetic nanoparticles enables microRNA detection in blood. Nature Nanotechnology, 2018, 13, 1066-1071.	15.6	244

#	Article	IF	Citations
19	Î²-Tubulin carboxy-terminal tails exhibit isotype-specific effects on microtubule dynamics in human gene-edited cells. Life Science Alliance, 2018, 1, e201800059.	1.3	17
20	Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA/ROCK signaling and enhanced transendothelial migration. Oncogene, 2017, 36, 501-511.	2.6	25
21	An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance. International Journal of Molecular Sciences, 2017, 18, 1434.	1.8	103
22	MutY-Homolog (MYH) inhibition reduces pancreatic cancer cell growth and increases chemosensitivity. Oncotarget, 2017, 8, 9216-9229.	0.8	13
23	Abstract 5484: Structural domains of Î²III-Tubulin regulate multiple stress responses and influence cell growth and survival in glucose-deprived non-small cell lung cancer. , 2017, , .		0
24	Abstract 4037: High throughput kinase inhibitor screen reveals novel inhibitor combinations acting in synergy withTUBB3/Î²III-tubulin suppression in non-small cell lung cancer. , 2017, , .		0
25	Delineating the Role of Î²IV-Tubulins in Pancreatic Cancer: Î²IVb-Tubulin Inhibition Sensitizes Pancreatic Cancer Cells to Vinca Alkaloids. Neoplasia, 2016, 18, 753-764.	2.3	18
26	Î²III-Tubulin alters glucose metabolism and stress response signaling to promote cell survival and proliferation in glucose-starved non-small cell lung cancer cells. Carcinogenesis, 2016, 37, 787-798.	1.3	28
27	MutY-Homolog modulates pancreatic cancer cell survival and chemoresistance. Pancreatology, 2016, 16, S5.	0.5	0
28	A Rationally Optimized Nanoparticle System for the Delivery of RNA Interference Therapeutics into Pancreatic Tumors in Vivo. Biomacromolecules, 2016, 17, 2337-2351.	2.6	68
29	Analyses of Tumor Burden In Vivo and Metastasis Ex Vivo Using Luciferase-Expressing Cancer Cells in an Orthotopic Mouse Model of Neuroblastoma. Methods in Molecular Biology, 2016, 1372, 61-77.	0.4	8
30	The BET bromodomain inhibitor exerts the most potent synergistic anticancer effects with quinone-containing compounds and anti-microtubule drugs. Oncotarget, 2016, 7, 79217-79232.	0.8	17
31	Exploiting base excision repair to improve therapeutic approaches for pancreatic cancer. Frontiers in Nutrition, 2015, 2, 10.	1.6	22
32	TUBB3/Î²III-Tubulin Acts through the PTEN/AKT Signaling Axis to Promote Tumorigenesis and Anoikis Resistance in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2015, 75, 415-425.	0.4	72
33	Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer. Oncotarget, 2015, 6, 12020-12034.	0.8	51
34	Î²III-Tubulin: A novel mediator of chemoresistance and metastases in pancreatic cancer. Oncotarget, 2015, 6, 2235-2249.	0.8	57
35	RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model. Oncogene, 2014, 33, 882-890.	2.6	59
36	Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Frontiers in Physiology, 2014, 5, 2.	1.3	57

#	Article	IF	Citations
37	Role of pancreatic stellate cells in chemoresistance in pancreatic cancer. Frontiers in Physiology, 2014, 5, 141.	1.3	122
38	Microtubules and Their Role in Cellular Stress in Cancer. Frontiers in Oncology, 2014, 4, 153.	1.3	296
39	Drug delivery: Beyond active tumour targeting. Nanomedicine: Nanotechnology, Biology, and Medicine, 2014, 10, 1131-1137.	1.7	61
40	Movers and shakers: cell cytoskeleton in cancer metastasis. British Journal of Pharmacology, 2014, 171, 5507-5523.	2.7	453
41	Dextran-Based Doxorubicin Nanocarriers with Improved Tumor Penetration. Biomacromolecules, 2014, 15, 262-275.	2.6	111
42	Abstract 2076: Î²III-tubulin is required for the tumorigenic phenotype and resistance to anoikis via the PTEN/AKT signaling axis in non-small cell lung cancer. , 2014, , .		0
43	Abstract 4987: Stathmin regulates cell migration, invasion and transendothelial migration via RhoA activation in neuroblastoma. , 2014, , .		0
44	Abstract 326: Î²III-Tubulin and cell survival: Novel role in endoplasmic reticulum stress and autophagy in non-small cell lung cancer. , 2014, , .		0
45	Effective Delivery of siRNA into Cancer Cells and Tumors Using Well-Defined Biodegradable Cationic Star Polymers. Molecular Pharmaceutics, 2013, 10, 2435-2444.	2.3	94
46	In Vivo Delivery of RNAi by Reducible Interfering Nanoparticles (iNOPs). ACS Medicinal Chemistry Letters, 2013, 4, 720-723.	1.3	15
47	Microtubules, Drug Resistance, and Tumorigenesis. , 2012, , 223-240.		1
48	Abstract 1969: Silencing Î±III-tubulin by RNA interfering nanoparticles in non-small cell lung cancer. , 2012, , .		0
49	Abstract 1444: Stathmin suppression influences ROCK signaling and reduces cell invasion and metastasis in neuroblastoma. , 2012, , .		0
50	Dicer-Labile PEG Conjugates for siRNA Delivery. Biomacromolecules, 2011, 12, 4301-4310.	2.6	20
51	Block Co-polymer Nanoparticles with Degradable Cross-Linked Core and Low-Molecular-Weight PEG Corona for Anti-tumour Drug Delivery. Journal of Biomaterials Science, Polymer Edition, 2011, 22, 1001-1022.	1.9	6
52	Silencing microRNA by interfering nanoparticles in mice. Nucleic Acids Research, 2011, 39, e38-e38.	6.5	59
53	Specific Î²-Tubulin Isotypes Can Functionally Enhance or Diminish Epothilone B Sensitivity in Non-Small Cell Lung Cancer Cells. PLoS ONE, 2011, 6, e21717.	1.1	38
54	Microtubule Dynamics, Mitotic Arrest, and Apoptosis: Drug-Induced Differential Effects of Î²III-Tubulin. Molecular Cancer Therapeutics, 2010, 9, 1339-1348.	1.9	89

#	Article	IF	Citations
55	Î²III-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Nonâ€“Small Cell Lung Cancer. Cancer Research, 2010, 70, 4995-5003.	0.4	99
56	Design and Assembly of New Nonviral RNAi Delivery Agents by Microwave-Assisted Quaternization (MAQ) of Tertiary Amines. Bioconjugate Chemistry, 2010, 21, 1581-1587.	1.8	7
57	Nanotubes Functionalized with Lipids and Natural Amino Acid Dendrimers: A New Strategy to Create Nanomaterials for Delivering Systemic RNAi. Bioconjugate Chemistry, 2010, 21, 56-63.	1.8	65
58	Abstract 5026: Î²III-Tubulin regulates expression of proteins involved in tumorigenesis and metastasis in non-small cell lung cancer. , 2010, , .		0
59	The role of NF-ÂB activation in the pathogenesis of acute pancreatitis. Gut, 2008, 57, 259-267.	6.1	234
60	Triptolide Induces Pancreatic Cancer Cell Death via Inhibition of Heat Shock Protein 70. Cancer Research, 2007, 67, 9407-9416.	0.4	278
61	TRIPTOLIDE INHIBITS TUMOR GROWTH AND LOCAL-REGIONAL SPREAD IN VIVO VIA INCREASED APOPTOSIS AND DECREASED HEAT SHOCK PROTEIN 70 (HSP70). Pancreas, 2007, 35, 423.	0.5	0
62	DELIVERY OF siRNA TO PANCREATIC CANCER CELLS USING NOVEL NON-VIRAL BIODEGRADABLE NANOPARTICLES. Pancreas, 2007, 35, 416.	0.5	0
63	Design and Creation of New Nanomaterials for Therapeutic RNAi. ACS Chemical Biology, 2007, 2, 237-241.	1.6	75
64	Triptolide a potential therapeutic candidate for pancreatic cancer. Journal of the American College of Surgeons, 2007, 205, S94.	0.2	2
65	Pancreatic MAP Kinase Pathways and Acetaldehyde. Novartis Foundation Symposium, 2007, 285, 200-216.	1.2	21
66	Vitamin A inhibits pancreatic stellate cell activation: implications for treatment of pancreatic fibrosis. Gut, 2006, 55, 79-89.	6.1	131
67	Pancreatic stellate cell migration: role of the phosphatidylinositol 3-kinase (PI3-kinase) pathway. Biochemical Pharmacology, 2004, 67, 1215-1225.	2.0	75
68	Desmoplastic Reaction in Pancreatic Cancer. Pancreas, 2004, 29, 179-187.	0.5	530
69	Parathyroid hormone-related peptide modulates signal pathways in skin and hair follicle cells. Experimental Dermatology, 2003, 12, 389-395.	1.4	18
70	Oxidant stress induces the p38 mitogen activated protein kinase (p38 MAPK) signalling pathway in pancreatic stellate cells. Gastroenterology, 2003, 124, A616.	0.6	0
71	Rat pancreatic stellate cells secrete matrix metalloproteinases: implications for extracellular matrix turnover. Gut, 2003, 52, 275-282.	6.1	244
72	Pancreatic Stellate Cell Activation by Ethanol and Acetaldehyde: Is it Mediated by the Mitogen-Activated Protein Kinase Signaling Pathway?. Pancreas, 2003, 27, 150-160.	0.5	79

#	Article	IF	Citations
73	Cell migration: a novel aspect of pancreatic stellate cell biology. Gut, 2003, 52, 677-682.	6.1	94
74	Dietary fat manipulation and signal transduction in ovine skin. Comparative Biochemistry and Physiology - B Biochemistry and Molecular Biology, 1998, 120, 571-577.	0.7	1